BRCA1 and breast carcinoma: In the case of miR-182, which has been described to be upregulated in breast carcinoma, to target specifically BRCA1 gene and to be involved in the resistance to PARP-1 inhibitors [41], [42], we identified a relationship between miR-182 expression and clinical outcome.